Methicillin-resistant Staphylococcus aureus (MRSA) in hospitals: latest trends and treatments based on bacteriophages.

Even though antibiotic resistance in bacteria is a natural phenomenon, the alarming increase in pathogenic bacteria refractory to a wide range of antimicrobials is attracting attention worldwide. Indeed, the World Health Organization (WHO) has recently published a list of priority pathogens for whic...

Descripción completa

Detalles Bibliográficos
Autores: Álvarez, A., Fernández Llamas, Lucía, Gutiérrez, Diana, Iglesias, Beatriz, Rodríguez González, Ana, García Suárez, María Pilar
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/197834
Acceso en línea:http://hdl.handle.net/10261/197834
Access Level:acceso abierto
Palabra clave:Staphylococcus aureus
Antibiotic resistance
Phage therapy
id ES_4a590fdbef0b6122dea73cedf61b8d83
oai_identifier_str oai:digital.csic.es:10261/197834
network_acronym_str ES
network_name_str España
repository_id_str
spelling Methicillin-resistant Staphylococcus aureus (MRSA) in hospitals: latest trends and treatments based on bacteriophages.Álvarez, A.Fernández Llamas, LucíaGutiérrez, DianaIglesias, BeatrizRodríguez González, AnaGarcía Suárez, María PilarStaphylococcus aureusAntibiotic resistancePhage therapyEven though antibiotic resistance in bacteria is a natural phenomenon, the alarming increase in pathogenic bacteria refractory to a wide range of antimicrobials is attracting attention worldwide. Indeed, the World Health Organization (WHO) has recently published a list of priority pathogens for which new antimicrobial alternatives are urgently needed. Amongst these pathogens, methicillin-resistant Staphylococcus aureus (MRSA) strains are perhaps the best known by the general public. In addition to its potential to acquire antibiotic resistance, S. aureus can produce a high number of virulence factors, such as hemolysins, enterotoxins and proteases, and exhibits the ability to form biofilms as well as to evolve into different clones that can spread and colonize new environments. This review provides a brief overview of the latest options in antibacterial therapies, mainly focusing on phage therapy. In this regard, the current stage of research about antimicrobial compounds based on bacteriophages and endolysins against MRSA infections are shown and discussed.Peer reviewedAmerican Society for MicrobiologyMinisterio de Ciencia, Innovación y Universidades (España)Fernández, Lucía [0000-0002-7383-7595]Gutiérrez, Diana [0000-0002-0473-1447]García Suárez, María Pilar [0000-0003-1213-8165]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202020202019info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_dcae04bchttp://hdl.handle.net/10261/197834reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttp://dx.doi.org/10.1128/JCM.01006-19Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/1978342026-05-22T06:33:51Z
dc.title.none.fl_str_mv Methicillin-resistant Staphylococcus aureus (MRSA) in hospitals: latest trends and treatments based on bacteriophages.
title Methicillin-resistant Staphylococcus aureus (MRSA) in hospitals: latest trends and treatments based on bacteriophages.
spellingShingle Methicillin-resistant Staphylococcus aureus (MRSA) in hospitals: latest trends and treatments based on bacteriophages.
Álvarez, A.
Staphylococcus aureus
Antibiotic resistance
Phage therapy
title_short Methicillin-resistant Staphylococcus aureus (MRSA) in hospitals: latest trends and treatments based on bacteriophages.
title_full Methicillin-resistant Staphylococcus aureus (MRSA) in hospitals: latest trends and treatments based on bacteriophages.
title_fullStr Methicillin-resistant Staphylococcus aureus (MRSA) in hospitals: latest trends and treatments based on bacteriophages.
title_full_unstemmed Methicillin-resistant Staphylococcus aureus (MRSA) in hospitals: latest trends and treatments based on bacteriophages.
title_sort Methicillin-resistant Staphylococcus aureus (MRSA) in hospitals: latest trends and treatments based on bacteriophages.
dc.creator.none.fl_str_mv Álvarez, A.
Fernández Llamas, Lucía
Gutiérrez, Diana
Iglesias, Beatriz
Rodríguez González, Ana
García Suárez, María Pilar
author Álvarez, A.
author_facet Álvarez, A.
Fernández Llamas, Lucía
Gutiérrez, Diana
Iglesias, Beatriz
Rodríguez González, Ana
García Suárez, María Pilar
author_role author
author2 Fernández Llamas, Lucía
Gutiérrez, Diana
Iglesias, Beatriz
Rodríguez González, Ana
García Suárez, María Pilar
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Ministerio de Ciencia, Innovación y Universidades (España)
Fernández, Lucía [0000-0002-7383-7595]
Gutiérrez, Diana [0000-0002-0473-1447]
García Suárez, María Pilar [0000-0003-1213-8165]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Staphylococcus aureus
Antibiotic resistance
Phage therapy
topic Staphylococcus aureus
Antibiotic resistance
Phage therapy
description Even though antibiotic resistance in bacteria is a natural phenomenon, the alarming increase in pathogenic bacteria refractory to a wide range of antimicrobials is attracting attention worldwide. Indeed, the World Health Organization (WHO) has recently published a list of priority pathogens for which new antimicrobial alternatives are urgently needed. Amongst these pathogens, methicillin-resistant Staphylococcus aureus (MRSA) strains are perhaps the best known by the general public. In addition to its potential to acquire antibiotic resistance, S. aureus can produce a high number of virulence factors, such as hemolysins, enterotoxins and proteases, and exhibits the ability to form biofilms as well as to evolve into different clones that can spread and colonize new environments. This review provides a brief overview of the latest options in antibacterial therapies, mainly focusing on phage therapy. In this regard, the current stage of research about antimicrobial compounds based on bacteriophages and endolysins against MRSA infections are shown and discussed.
publishDate 2019
dc.date.none.fl_str_mv 2019
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_dcae04bc
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/197834
url http://hdl.handle.net/10261/197834
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv http://dx.doi.org/10.1128/JCM.01006-19
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv American Society for Microbiology
publisher.none.fl_str_mv American Society for Microbiology
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407480277106688
score 15.812455

Similares en LA Referencia